pharmaphorum20 小时
Boehringer says R&D pipeline is the best in its long history
Top of the agendas was chronic kidney disease (CKD), an area where Boehringer is already making an impact with blockbuster SGLT2 inhibitor Jardiance (empagliflozin). Jardiance was originally ...
pharmaphorum20 小时
AZ drug for hard-to-treat heart failure has mixed results in trial
Unfortunately while strides forward have been made in improving survival in heart failure with reduced ejection fraction (HFrEF) – including with AstraZeneca's SGLT2 inhibitor Farxiga/Forxiga ...